论文信息 - Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease. - 字舞流文

Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease.

Paul Cumming | Per Borghammer | Yoshitaka Kumakura | P. Cumming | Y. Kumakura | P. Borghammer

[1] D Oakes,et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease , 2003, Experimental Neurology.

[2] Karl Herholz,et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. , 2005, Archives of neurology.

[3] Arne Møller,et al. Quantitative [18F]Fluorodopa/PET and Histology of Fetal Mesencephalic Dopaminergic Grafts to the Striatum of MPTP-Poisoned Minipigs , 2002, Cell transplantation.

[4] H. Kimura,et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.

[5] B. Långström,et al. Regulation of dopaminergic activity in early Parkinson's disease , 1999, Annals of neurology.

[6] J S Rakshi,et al. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[7] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[8] Merja Haaparanta,et al. Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study , 2001, Movement disorders : official journal of the Movement Disorder Society.